Appendix 3Y-Brendan de Kauwe
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity
Race Oncology Limited
ABN
61 149 318 749
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director
Brendan de Kauwe
Date of last notice
13 July 2016
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Direct or indirect interest
Indirect
Nature of indirect interest
(including registered holder)
Attollo Investments Pty Ltd <Attollo Investment A/C> Director related entity
Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change
22 November 2017
No. of securities held prior
to change
590,000 fully paid ordinary shares escrowed for 24 months from
quotation.
Options
Class
Number acquired
Number disposed
Value/Consideration
includes brokerage/gst
1,000,000 options exercisable at $0.49, expiring 22 November
2019.
1,000,000 options exercisable at $0.65, expiring 22 November
2019.
Nil
Note: If consideration is non-cash, provide
details and estimated valuation
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after
change
590,000 fully paid ordinary shares escrowed for 24 months from
quotation.
1,000,000 options exercisable at $0.49, expiring 22 November
2019.
1,000,000 options exercisable at $0.65, expiring 22 November
September 2019.
Nature of change
Issue of options following approval by shareholders at the
annual general meeting held on 21 November 2017.
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed
in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A
Date of change
N/A
No. and class of securities to N/A
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Note: If consideration is non-cash, provide details and an
estimated valuation
Interest after change
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed No.
above traded during a +closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade N/A
to proceed during this period?
If prior written clearance was provided, on what date was this N/A
provided?
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Share your feedback
Discover